Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.41 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MME | P08473 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.34 |
| ▸ | CPA1 | P15085 | 2/20 | 0.34 |
| ▸ | CPB1 | P15086 | 1/20 | 0.34 |
| ▸ | CPA3 | P15088 | 1/20 | 0.34 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.34 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22242591 | 0.86 | FOLH1 (0.46) | FOLH1SLC22A6TDP1MMESMN1; SMN2 | |
| SCHEMBL19615624 | 0.83 | SLC1A1 (0.40) | SLC1A1OR51E2 | |
| SCHEMBL542313 | 0.78 | FOLH1 (0.56) | FOLH1SLC22A6TDP1MMESMN1; SMN2 | |
| SCHEMBL9668057 | 0.77 | MMP2 (0.40) | FOLH1SLC22A6TDP1SMN1; SMN2SLC1A1 | |
| SCHEMBL28920282 | 0.76 | FOLH1 (0.54) | FOLH1SLC22A6TDP1MMESMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL6779003 | 0.76 | FOLH1 (0.54) | FOLH1SLC22A6TDP1MMESMN1; SMN2 | |
| SCHEMBL9270192 | 0.74 | MME (0.44) | FOLH1SLC22A6TDP1MMESMN1; SMN2 | |
| SCHEMBL16115234 | 0.73 | MME (0.49) | FOLH1SLC22A6MMECPA1 | |
| SCHEMBL28324581 | 0.72 | LMNA (0.41) | FOLH1SLC22A6TDP1MMESMN1; SMN2 | |
| SCHEMBL16115238 | 0.72 | MME (0.47) | FOLH1SLC22A6MMECPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120322906-A1 | POLYMER AND METHODS OF PREPARING AND USING A POLYMER | CARGILL, INCORPORATED (US) | 2012-12-20 | — | — | US | disclosed |
| WO-2012166842-A1 | INCREASING PRODUCT YIELD AND/OR THROUGHPUT BY SUPERSATURATION OF SUBSTRATE | CARGILL, INCORPORATED (US) | 2012-12-06 | — | — | WO | disclosed |
| WO-2012166406-A1 | INCREASING PRODUCT YIELD AND/OR THROUGHPUT BY SUPERSATURATION OF SUBSTRATE | CARGILL, INCORPORATED (US) | 2012-12-06 | — | — | WO | disclosed |
| EP-2519406-A1 | A POLYMER AND METHODS OF PREPARING AND USING A POLYMER | Cargill, Incorporated (US) | 2012-11-07 | — | — | EP | disclosed |
| US-20120270281-A1 | BIOREACTOR PERFORMANCE IN THE PRODUCTION OF MONATIN | CARGILL, INCORPORATED (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120264948-A1 | MEMBRANE SEPARATION AND PURIFICATION OF MONATIN | CARGILL, INCORPORATED (US) | 2012-10-18 | — | — | US | disclosed |
| WO-2011082363-A1 | MEMBRANE SEPARATION AND PURIFICATION OF MONATIN | CARGILL, INCORPORATED (US) | 2011-07-07 | — | — | WO | disclosed |
| WO-2011082353-A1 | SEPARATION AND PURIFICATION OF MONATIN | CARGILL, INCORPORATED (US) | 2011-07-07 | — | — | WO | disclosed |
| WO-2011082365-A2 | IMPROVED BIOREACTOR PERFORMANCE IN THE PRODUCTION OF MONATIN | CARGILL, INCORPORATED (US) | 2011-07-07 | — | — | WO | disclosed |
| WO-2011082351-A1 | A POLYMER AND METHODS OF PREPARING AND USING A POLYMER | CARGILL, INCORPORATED (US) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264948-A1 | MEMBRANE SEPARATION AND PURIFICATION OF MONATIN | MON2, STOM, MLEC | FOLH1 1528/4885SLC22A6 2621/4885TDP1 4649/4885 |
| US-20120322906-A1 | POLYMER AND METHODS OF PREPARING AND USING A POLYMER | MON2, STOM, LCP1 | FOLH1 849/4885SLC22A6 3049/4885TDP1 928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.